A Rice University student decided to use his data science skills for good. Photo courtesy of Biokind Analytics

For Alex Han, it all started with peanut butter.

Han was a high school student in Korea when he learned that the spread is a pure odorant that could be used to test smell in each hemisphere of the brain—issues on the left side was thought to be a predictor for Alzheimer’s disease. He later learned that the method wasn’t as airtight as previously thought, but Han was hooked. Alzheimer’s research became the teenager’s passion. While still in high school, Han began volunteering for Alzheimer’s Los Angeles, translating their brochures into Korean.

When it came time to choose a college, Han says Rice University appealed to him for many reasons.

“I loved the atmosphere. I loved the campus—it’s so beautiful. The diverse food, the people, I even liked the highway,” he says of Houston. “In Korea, everything is so close and compact. I loved the whole scenario of the city.”

A scholarship was also part of the appeal, as well as the pull of the world’s largest medical center. Han’s instincts were correct. Now, a junior at Rice, he has been working at renowned geneticist Huda Zoghbi’s Baylor College of Medicine lab for almost two years.

But dividing his obligations between full-time studies and his wet lab position wasn’t enough to keep Han’s active mind occupied. Last May, the statistics and biochemistry student began another endeavor that uses both his specialties. It was then that he founded Biokind Analytics. The nonprofit was designed to explore how data science can support health care nonprofits.

Han reached out to Alzheimer’s Los Angeles to offer his data analysis services on a volunteer basis and was shocked that the association had never considered it before.

“I was really surprised—even small stores and restaurants use statistics to boost their profits. [Alzheimer’s Los Angeles] receive a couple million dollars every year in donations. They have data stores but hadn’t really capitalized yet in the area of analytics.”

Han, along with a small team of Rice students, including vice president Zac Andrews and development director Masha Zaitsev, made Alzheimer’s Los Angeles a pet project, analyzing geospatial trends in its donorship and interpreting the past year’s donation trends. “We wanted to see if the demand was the same in Houston. We found that this pattern was consistent. A lot of nonprofits are willing to have us analyze the data sets they’ve already been tracking and provide data analysis for healthcare nonprofits.”

Less than a year after Han established Biokind Analytics, the 501(c)(3) already has seven chapters on college campuses around the country. From UC Davis and San Diego in the West to Brown University and the University of Virginia on the East Coast, the data science students have helped a diverse range of medical nonprofits, mostly based in the Houston area. They run the gamut from ALS Association of Texas to Nora’s Home, which serves organ failure and transplant patients.

Biokind Analytics has now completed seven projects and analyzed $100 million in funds. Each student group includes four to six members, mostly majors in the worlds of statistics, data science, and biochemistry, all working with the help of faculty advisors. At a total of about 35 students nationwide, Han says that he’s dedicated to growing at a steady pace to avoid potentially expanding too fast, too soon.

Another question for the future is what will happen to Biokind Analytics when Han completes his undergraduate studies in 2024. He plans to continue his medical studies with the goal of one day becoming a physician specializing in Alzheimer’s who uses data analytics to aid in patient care. But no matter how active Han continues to be in the nonprofit he started, his stated attachment to the cause and a growing group of both student leaders and healthcare associations eager for their services are sure to keep Biokind Analytics active long after graduation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston medtech firm secures $30M for neurosurgical robot

stroke surgery

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.